Combining incretin-based drugs and RAAS inhibitors: More cons than pros?

The Lancet Diabetes and Endocrinology

Volumn 2, Issue 9, 2014, Pages 684-685

  Tonneijck, Lennart ^a   Muskiet, Marcel H A ^a   Smits, Mark M ^a   van Raalte, Daniël H ^a   Diamant, Michaela ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INCRETIN; NEUROPEPTIDE Y; RENIN; RENIN INHIBITOR; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

CARDIOVASCULAR RISK; DRUG SAFETY; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PLASMA RENIN ACTIVITY; PROTEIN DEGRADATION; RECEPTOR UPREGULATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; ANTAGONISTS AND INHIBITORS; BLOOD; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; TREATMENT OUTCOME;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; INCRETINS; RENIN; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84908342935     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(14)70167-6     Document Type: Note

References (10)

1. Muskiet MHA, Smits MM, Morsink LM, Diamant M The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?. Nat Rev Nephrol 2014, 10:88-103.
2. Skov J, Dejgaard A, Frøkiær J, et al. Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men. J Clin Endocrinol Metab 2013, 98:E664-E671.
3. Gutzwiller J-P, Tschopp S, Bock A, et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 2004, 89:3055-3061.
4. Pyke C, Heller RS, Kirk RK, et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 2014, 155:1280-1290.
5. Molitch ME, Adler AI, Flyvbjerg A, et al. Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes. Kidney Int 2014, published online April 30. 10.1038/ki.2014.128.
6. Devin JK, Pretorius M, Nian H, Yu C, Billings FT, Brown NJ Substance P increases sympathetic activity during combined angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibition. Hypertension 2014, 63:951-957.
7. Marney A, Kunchakarra S, Byrne L, Brown NJ Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans. Hypertension 2010, 56:728-733.
8. Jackson EK Dipeptidyl peptidase IV inhibition alters the hemodynamic response to angiotensin-converting enzyme inhibition in humans with the metabolic syndrome. Hypertension 2010, 56:581-583.
9. Scirica BM, Raz I, Cavender MA, et al. An analysis of the SAVOR trial: saxagliptin and heart failure in patients with type 2 diabetes. American Heart Association Scientific Sessions; Dallas, TX, USA; Nov 16-20, 2013. 17503.
10. McMurray J. Effect of vildagliptin on left ventricular function in patients with type 2 diabetes and congestive heart failure. Heart Failure Congress 2013; Lisbon, Portugal; May 25-28, 2013. 2013:99.